Clinical trials: Geriatric Cardiology
Heart Failure, Diastolic, Obesity
Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)
The purpose of this study is to examine the effects of weight loss via hypocaloric diet (CR)and aerobic exercise (AT) compared to the effects of weight loss via hypocaloric diet (CR), aerobic training (AT)and resistance training…
- Trial name
- SECRET-II (NCT02636439)
- Testing
- dietary, aerobic and resistance training, dietary, and aerobic exercise
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Wake Forest University Health Sciences
Fabry Disease
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants
- Trial name
- NCT04049760
- Testing
- migalastat HCl 150 mg
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Amicus Therapeutics
Heart Failure
Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction
The primary objective of this study is to determine whether treatment with aliskiren (300 mg) compared to placebo will improve treadmill exercise time in older (age ≥ 55 years) patients with heart failure and normal ejection…
- Trial name
- Aliskiren (NCT00982033)
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma, Relapse
Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to…
- Conditions
- Multiple Myeloma, Relapse, Refractory, Aging
- Trial name
- NCT05911321
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hypertension, Systolic, Cerebrovascular Disease
Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People
This randomized clinical trial examines if lowering and maintaining 24-hour ambulatory systolic blood pressure to <130 mmHg (intensive control) versus <145 mmHg (standard control) slows/halts the progression of deterioration of…
- Trial name
- NCT01650402
- Testing
- Anti-hypertensive therapy to SBP 130 mm Hg, Anti-hypertensive therapy to SBP 145 mm Hg
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- UConn Health
Myocardial Infarction, Cardiovascular Disease
Secondary Prevention of Cardiovascular Disease in the Elderly Trial
The purpose of this study is to evaluate the efficacy of a polypill strategy containing aspirin (100 mg), ramipril (2.5, 5 or 10 mgs), and atorvastatin (40 mgs) compared with the standard of care (usual care according to the…
- Trial name
- SECURE (NCT02596126)
- Testing
- Cardiovascular Polypill, Treatment Prevention for Secondary CV
- Where
- 113 sites in Czechia, France and 5 more
- Volunteers
- 2,499 people
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Cardiovascular, Dyslipidemia
Cardiovascular Events Based On Statin Initiation In The Elderly
The purpose of this study is to compare rates and risk of primary cardiovascular events among elderly patients newly initiating therapy with atorvastatin or simvastatin.
- Trial name
- NCT01304641
- Testing
- Atorvastatin Initiators, Simvastatin Initiators
- Volunteers
- 31,603 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anemia
Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling…
- Trial name
- NCT00286182
- Testing
- Erythropoietin alpha
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Mathew S. Maurer
Hypertension
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.
- Trial name
- NCT00368277
- Testing
- Aliskiren, Ramipril, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 901 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.
- Trial name
- GENERATIONS (NCT01107912)
- Testing
- prasugrel, clopidogrel
- Where
- 7 sites in United States, Ireland and 2 more
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, Alzheimer's Disease
Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training
The purpose of this pilot study will be to test whether Kundalini yoga (KY) and Kirtan Kriya (KK) yogic meditation is superior to Memory Enhancement Training (MET) for improving cognitive functioning, health (including…
- Trial name
- NCT03503669
- Testing
- Memory Training, Kundalini yoga and meditation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Los Angeles
Heart Failure
Cardiac Resynchronization in the Elderly
This pilot will enroll 50 HF patients (age ≥ 75 years) undergoing CRT device implantation at the hospitals of the University of Pittsburgh Medical Center, Duke University, Ohio State University, and the VA Pittsburgh Healthcare…
- Trial name
- NCT03031847
- Testing
- Cardiac Resynchronization Therapy Pacemaker, Cardiac Resynchronization Therapy Defibrillator
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- Samir Saba
Multiple Myeloma, Myeloma
Geriatric-assessment Interventions to Address Functional Deficits in Older Adults w Multiple Myeloma
Myeloma is the second most common type of blood cancer in the United States. Myeloma most commonly affects older adults. While some younger individuals do get myeloma, the average age when people are first diagnosed with myeloma…
- Conditions
- Multiple Myeloma, Myeloma, Disability Physical, Disabilities Multiple
- Trial name
- NCT04999085
- Testing
- Supportive care interventions
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hypertension
A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED)
This study will evaluate methodologies for measuring pedal edema associated with calcium channel blockers in middle-aged and elderly subjects and patients with hypertension.
- Trial name
- NCT00789321
- Testing
- Comparator: amlodipine besylate
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
- Trial name
- NCT01615198
- Testing
- Olmesartan, LCZ696
- Where
- 79 sites in China, Hong Kong and 5 more
- Volunteers
- 588 people
- Sponsor
- Novartis Pharmaceuticals
Aging, Hyperthermia
Cardiovascular Responses to Heat Waves in the Elderly
The purpose of this study is to assess the cardiovascular responses of the elderly to heat wave conditions
- Trial name
- NCT04538144
- Testing
- Hot and Humid Trial, Hot and Dry Trial
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension.
The purpose of the study is to evaluate the safety and efficacy of initial treatment therapy with valsartan/hydrochlorothiazide (HCTZ) versus the initial treatment therapy with monotherapies (valsartan or HCTZ) in the very…
- Trial name
- NCT00698646
- Testing
- Valsartan + HCTZ, Valsartan, HCTZ
- Where
- 20 sites in United States
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Fabry Disease
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
This was an open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric participants 12 to <18 years of age with Fabry disease and amenable gene…
- Trial name
- NCT03500094
- Testing
- Migalastat HCl 150 mg
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 22 people
- Sponsor
- Amicus Therapeutics
Hypertension
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
- Trial name
- NCT00706134
- Testing
- Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg
- Where
- 8 sites in Argentina, Czechia and 6 more
- Volunteers
- 756 people
- Sponsor
- Novartis
Atrial Fibrillation
This Study Observes the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) in Elderly Patients With a Heart Rhythm Disorder in Spain
This is an observational, multicenter and cross-sectional study in Non-valvular atrial fibrillation (NVAF) elderly patients currently on Non-vitamin K antagonist oral anticoagulant (NOAC) treatment for their stroke prevention.
- Trial name
- NCT03993119
- Testing
- Non-vitamin K antagonist oral anticoagulant
- Where
- 45 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Boehringer Ingelheim